ATX

AMPLIA THERAPEUTICS LIMITED - News & Media

0.00%

15.0¢

Market Cap $76.99M

Healthcare Biotechnology

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Articles & Videos

Amplia Therapeutics and ANZGOG to undertake ovarian cancer study

Amplia Therapeutics and the ANZOG have entered into an agreement to conduct a new clinical study into ovarian cancer.

08 May 2026 14:28 (AEST)

Amplia tanks over -20% as ACCENT trial data underwhelms

The dangers of biotech were on display on Wednesday as Amplia Therapeutics (ASX:ATX), developing a cancer treatment called ACCENT, has failed to meet market expectations on the Wednesday session.

06 Aug 2025 12:08 (AEST)

Amplia pops 40% on liquidity surge as chemo combo proves successful

Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes...

15 May 2025 13:31 (AEST)

Amplia moves to next stage of cancer drug trial for narmafotinib

Amplia Therapeutics Ltd is set to move further through its Phase 2a trial for cancer drug narmafotinib, with four patients showing a response.

06 Aug 2024 09:27 (AEST)

Amplia enrols new patients to progress testing for pancreatic cancer drug

Amplia Therapeutics Ltd has enrolled a new group of patients to test the efficacy of its drug narmafotinib in treatment of pancreatic cancer.

03 Jul 2024 11:57 (AEST)

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful completion of phase 1b of the trial

27 Mar 2024 16:11 (AEDT)

Ampila Therapeutics wins US FDA green tick for investigational new drug status

Ampila (ASX:ATX) has told the market it is the recipient of a positive clearance from the US FDA regarding an application for IND status.

18 Jan 2024 11:16 (AEDT)

Amplia Therapeutics mints $2.4m R&D tax benefit

Amplia Therapeutics (ASX:ATX) has confirmed a $2.4 million R&D tax benefit on the back of research using the company's FAK inhibitors.

20 Oct 2023 10:46 (AEDT)

Amplia Therapeutics (ASX:ATX) receives grant funding to support research collaboration with CSIRO

Amplia Therapeutics (ASX:ATX) has secured grant funding to support research collaboration with Australia's national science agency, CSIRO.

22 May 2023 11:18 (AEST)

Amplia Therapeatuics (ASX:ATX) recruits first patient in cohort three of trial for Pancreatic Cancer

Amplia Therapeutics (ASX:ATX) has recruited and dosed the first patient in cohort three of its ongoing ACCENT trial in pancreatic cancer.

19 Apr 2023 11:34 (AEST)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 15.0¢		Change 0.000(0.00%)		Mkt cap ! $76.99M

Open	High	Low	Volume
15.0¢	15.5¢	14.5¢	964.9K

Buyers (Bids)

Vol.	Price($)
88630	15.0¢

Sellers (Offers)

Price($)	Vol.
15.5¢	96897

Last trade - 16.10pm 07/08/2026 (20 minute delay)

ATX (ASX) Chart